HSHans Ulrich Schildhaus

Hans Ulrich Schildhaus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hans Ulrich Schildhaus has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sarkome

    by H.-U. Schildhaus, R. Büttner

  • Open Access

    qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL

    by Jana Fassunke, Marie-Christine Blum, Hans-Ulrich Schildhaus, Marc Zapatka, Benedikt Brors, Helen Künstlinger, Reinhard Büttner, Eva Wardelmann, Sabine Merkelbach-Bruse

    Background: Gastrointestinal stromal tumors (GIST) represent the most common mesenchymal tumors of the gastrointestinal tract. About 85% carry an activating mutation in the KIT or PDGFRA gene. Approximately 10% of GIST are so-called wild type GIST (wt-GIST) without mutations in the hot spots. In the present study we evaluated appropriate reference genes for the expression analysis of formalin-fixed, paraffin-embedded and fresh frozen samples from gastrointestinal stromal tumors. We evaluated the gene expression of KIT as well as of the alternative receptor tyrosine kinase genes FLT3, CSF1-R, PDGFRB, AXL and MET by qPCR. wt-GIST were compared to samples with mutations in KIT exon 9 and 11 and PDGFRA exon 18 in order to evaluate whether overexpression of these alternative RTK might contribute to the pathogenesis of wt-GIST. Results: Gene expression variability of the pooled cDNA samples is much lower than the single reverse transcription cDNA synthesis. By combining the lowest variability values of fixed and fresh tissue, the genes POLR2A, PPIA, RPLPO and TFRC were chosen for further analysis of the GIST samples. Overexpression of KIT compared to the corresponding normal tissue was detected in each GIST subgroup except in GIST with PDGFRA exon 18 mutation. Comparing our sample groups, no significant differences in the gene expression levels of FLT3, CSF1R and AXL were determined. An exception was the sample group with KIT exon 9 mutation. A significantly reduced expression of CSF1R, FLT3 and PDGFRB compared to the normal tissue was detected. GIST with mutations in KIT exon 9 and 11 and in PDGFRA exon 18 showed a significant PDGFRB downregulation. Conclusions: As the variability of expression levels for the reference genes is very high comparing fresh frozen and formalin-fixed tissue there is a strong need for validation in each tissue type. None of the alternative receptor tyrosine kinases analyzed is associated with the pathogenesis of wild-type or mutated GIST. It remains to be clarified whether an autocrine or paracrine mechanism by overexpression of receptor tyrosine kinase ligands is responsible for the tumorigenesis of wt-GIST.


  • Diagnostik gastrointestinaler Stromatumoren

    by E. Wardelmann, S. Merkelbach-Bruse, R. Büttner, P. Hohenberger, H.-U. Schildhaus

  • Open Access

    Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors

    by Sabine Merkelbach-Bruse, Wolfgang Dietmaier, Laszlo Füzesi, Andreas Gaumann, Florian Haller, Julia Kitz, Antje Krohn, Gunhild Mechtersheimer, Roland Penzel, Hans-Ulrich Schildhaus, et al.

    Mutation analysis of KIT and PDGFRA genes in gastrointestinal stromal tumors is gaining increasing importance for prognosis of GISTs and for prediction of treatment response. Several groups have identified specific mutational subtypes in KIT exon 11 associated with an increased risk of metastatic disease whereas GISTs with PDGFRA mutations often behave less aggressive. Furthermore, in advanced GIST disease with proven KIT exon 9 mutation the doubled daily dose of 800 mg imatinib increases the progression free survival and is now recommended both in the European and the American Guidelines. In Germany, there are still no general rules how to perform mutational analysis.


  • Inflammatorischer fibroider Polyp

    by H.-U. Schildhaus, S. Merkelbach-Bruse, E. Binot, R. Büttner, E. Wardelmann


  • Inflammatorische fibroide Polypen sind echte Neoplasien mit PDGFRA-Mutationen

    by H.-U. Schildhaus, R. Büttner, E. Binot, S. Merkelbach-Bruse, E. Wardelmann

    Inflammatorische fibroide Polypen (IFP) sind Proliferationen CD34-positiver Spindelzellen vor einem inflammatorischen Hintergrund in der Submukosa und Mukosa des Gastrointestinaltrakts. IFP kommen vor allem im Magen, aber auch im Dünndarm, Kolon und Ösophagus vor. Ätiologie und Pathogenese sind bislang unklar. 29 IFP aus Magen, Dünn- und Dickdarm wurden immunhistochemisch und molekularpathologisch untersucht. Für die Exons 10, 12, 14 und 18 von PDGFRA wurden Mutationsanalysen durchgeführt. In 20 Fällen (69%) wurden aktivierende Mutationen in den Exons 12 und 18 gefunden. Die Mutationstypen entsprachen dabei sämtlich bereits von gastrointestinalen Stromatumoren (GIST) bekannten aktivierenden Mutationen. D842V war der häufigste Mutationstyp. In den Exons 10 und 14 wurden keine aktivierenden Mutationen nachgewiesen. Die Mehrzahl der IFP weist aktivierende Mutationen in PDGFRA auf. Dieser Befund spricht dafür, dass es sich um echte Neoplasien (echte benigne Tumoren) und nicht um reaktive Läsionen handelt. Die Beziehungen zwischen PDGFRA-mutierten GISTs und IFP im Hinblick auf die Pathogenese sind noch unklar. Inflammatory fibroid polyps (IFP) are proliferations of CD34-positive spindle cells in the submucosa and mucosa of the gastrointestinal tract with an inflammatory infiltrate. IFP occur in the stomach, small bowel, colon and esophagus. To date, etiology and pathogenesis are unclear. A total of 29 IFP originating in the stomach, small bowel and colon were examined immunohistochemically, and mutational analyses of PDGFRA exons 10, 12, 14 and 18 were conducted. Activating mutations in PDGFRA exons 12 and 18 were found in 20 cases (69%). The mutational types are related to mutations known from gastrointestinal stromal tumors (GIST). D842V was the most frequent mutation. No activating mutations were found in exons 10 and 14. The majority of IFP reveal activating PDGFRA mutations. Our data indicate that IFP are true neoplasms (true benign tumors) and not reactive lesions. In terms of pathogenesis, the relationship between PDGFRA-mutant GISTs and IFP remains to be determined.


  • Maligner Müller-Mischtumor der Harnblase

    by H.-U. Schildhaus, G. Mikuz, C. Fisang, S. Steiner, R. Büttner, E. Wardelmann

    True mixed epithelial-mesenchymal tumors of the urinary bladder are exceedingly rare, and only two vesical adenosarcomas have been reported to date. These tumors originated from bladder endometriosis, and malignant transformation of endometriosis has been described, with endometrioid and clear-cell carcinomas being the most common malignancies. We report an unusual case of a malignant mixed Müllerian tumor with heterologous rhabdomyoblastic differentiation, which originated in the urinary bladder of a postmenopausal woman. To the best of our knowledge, such a neoplasm has not yet been reported in the literature.


  • Relevanz molekularpathologischer Befunde für die Diagnose, Prognose und Therapie von gastrointestinalen Stromatumoren

    by Eva Wardelmann, Sabine Merkelbach-Bruse, Reinhard Büttner, Peter Hohenberger, Peter Reichardt, Hans-Ulrich Schildhaus

  • Open Access

    The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction

    by Wilko I Staiger, Ulrich Ronellenfitsch, Georg Kaehler, Hans Ulrich Schildhaus, Antonia Dimitrakopoulou-Strauss, Matthias Hm Schwarzbach, Peter Hohenberger

    Gastrointestinal stromal tumors (GIST) of the esophagogastric junction might pose a major problem to surgical resection. If locally advanced, extended or multivisceral resection with relevant procedural-specific morbidity and mortality is often necessary.


    • 1 January 2007
      • Vol. 91, 165-8

    [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].

    by E Wardelmann, S Merkelbach-Bruse, R Büttner, H U Schildhaus

    Receptor tyrosine kinases have been shown to be a challenging target for the treatment of hematologic diseases and solid tumors. One very effective tyrosine kinase inhibitor is imatinib mesylate inhibiting the KIT receptor tyrosine kinase in gastrointestinal stromal tumors (GISTs) which often carry activating mutations in the KIT gene. Our own observations show that the location of the underlying mutations influence the response to treatment with imatinib. In Bonn, nearly 1000 GISTs have been characterized molecularily before and/or under treatment with tyrosine kinase inhibitors. Tumor-DNA was extracted from paraffine-embedded material, amplified in all known hot spots of KIT (exons 9, 11, 13, 14, 17) and PDGFRcx (exons 12, 14, 18) and sequenced directly. The best response to treatment with imatinib is achieved in GISTs with an underlying KIT mutation in exon 11 encoding the juxtamembranous domain. Exon 9 mutated GISTs respond in only half of the cases. GISTs with mutations in the tyrosine kinase domain 1 or 2 are very rare (less than 1%) and are thought to be resistant. PDGFRalpha-mutated GISTs are resistant when carrying the most common point mutation D842V (exon 18) and may respond when deletions occur in exon 18. Low response rates are achieved in tumors without detectable mutation. Under treatment, secondary KIT mutations may occur leading to resistance to treatment. The molecular status of GISTs plays a central role for treatment response. Its evaluation will be mandatory in the future at least in tumors with intermediate or high risk criteria.